Eisai files rufinamide for rare epilepsy in Japan after official nudge
This article was originally published in Scrip
Executive Summary
Following its identification by the government several years ago as a high-need drug, Eisai has submitted an approval application in Japan for rufinamide for the treatment of Lennox-Gastaut syndrome (LGS).